ARNI (Arno Therapeutics) Cyclically Adjusted PB Ratio: (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Arno Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arno Therapeutics  (OTCPK:ARNI) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Arno Therapeutics Cyclically Adjusted PB Ratio Related Terms


Arno Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Arno Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arno Therapeutics Cyclically Adjusted PB Ratio Chart

Arno Therapeutics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arno Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ARNI vs PLPL, BTHE, WIZP: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Arno Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arno Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arno Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arno Therapeutics's Cyclically Adjusted PB Ratio falls into.



Arno Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Arno Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2016 is calculated as:

For example, Arno Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2016 was:

Adj_Book=Book Value per Share/CPI of Sep. 2016 (Change)*Current CPI (Sep. 2016)
=-0.119/241.4280*241.4280
=-0.119

Current CPI (Sep. 2016) = 241.4280.

Arno Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
200603 -0.016 199.800 -0.019
200606 -0.017 202.900 -0.020
200609 -0.210 202.900 -0.250
200612 -0.223 201.800 -0.267
200703 -0.245 205.352 -0.288
200706 -0.262 208.352 -0.304
200709 0.000 208.490 0.000
200712 -2.912 210.036 -3.347
200803 -0.148 213.528 -0.167
200806 4.964 218.815 5.477
200809 4.177 218.783 4.609
200812 3.084 210.228 3.542
200912 0.618 215.949 0.691
201003 0.000 217.631 0.000
201006 0.000 217.965 0.000
201009 0.000 218.439 0.000
201012 3.305 219.179 3.640
201103 1.376 223.467 1.487
201106 1.019 225.722 1.090
201109 0.675 226.889 0.718
201112 0.299 225.672 0.320
201203 -0.230 229.392 -0.242
201206 -0.242 229.478 -0.255
201209 -0.865 231.407 -0.902
201212 -2.698 229.601 -2.837
201303 -2.664 232.773 -2.763
201306 -4.639 233.504 -4.796
201309 -5.339 234.149 -5.505
201312 -0.632 233.049 -0.655
201403 -0.597 236.293 -0.610
201406 -0.364 238.343 -0.369
201409 -0.303 238.031 -0.307
201412 -0.029 234.812 -0.030
201503 -0.148 236.119 -0.151
201506 -0.269 238.638 -0.272
201509 -0.257 237.945 -0.261
201512 -0.423 236.525 -0.432
201603 -0.097 238.132 -0.098
201606 -0.126 241.018 -0.126
201609 -0.119 241.428 -0.119

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arno Therapeutics Business Description

Address 200 Route 31 North, Suite 104, Flemington, NJ, USA, 08822
Arno Therapeutics Inc operates as a biopharmaceutical company. It develops drug candidates to treat patients with cancer and other life-threatening diseases. It develops pre-clinical and clinical-stage product under the following name: Onapristone, AR-42, and AR-12. Onapristone is indicated for endometrial, prostate and breast cancer indications, AR-42 is provided for hematological malignancies and solid tumors indications and AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets.